Team Aventiq Bio

Dr. Edwin Gershom

Dr. Edwin Gershom is a PhD-trained scientist (Pathology & Laboratory Medicine) with over a decade of experience in preclinical drug development and translational research across academia, biotech, and CRO environments. He brings a strong track record of advancing therapeutic programs from early discovery through IND-enabling studies and into clinical development.

Dr. Gershom specializes in designing and advising on preclinical strategies spanning efficacy, PK/PD, safety, and IND-enabling toxicology. He has supported biotech, pharmaceutical, and academic partners across oncology, immunology, and infectious diseases, ensuring programs are scientifically rigorous, clinically relevant, and positioned for successful translation

Prior to Aventiq Bio, Dr. Gershom played key roles at leading CRO and innovation organizations, where he guided end-to-end preclinical programs, aligned study designs with regulatory expectations, and integrated biomarker and translational strategies to de-risk clinical development.

At Aventiq Bio, Dr. Gershom partners with clients to navigate the complexity of the drug development landscape, bridging science, strategy, and execution to accelerate the path from discovery to clinic—and ultimately to improved patient outcomes.

Divyanshi Chhabra

With a Master’s in Pharmaceutics, Divyanshi brings a unique dual-lens to Aventiq Bio: a deep-rooted understanding of drug discovery nuances and the strategic foresight required to navigate the global CRO/CDMO landscape. She joined Aventiq to ensure our 'zero surprises' mission is embedded in every program we touch. By identifying technical 'pain points' especially in formulation and pre-formulation before they become costly delays, Divyanshi ensures alignment of technical reality with corporate milestones. She is dedicated to ensure that when you engage Aventiq Bio, your IND/CMC roadmap is backed by a strategy that is as scientifically rigorous as it is commercially sound.

K. Priyanka

Priyanka’s role at Aventiq Bio is to bridge the operational divide through radical transparency and relentless follow-through. Armed with an advanced degree in Biotechnology and CRO work experience, she leverages her background in molecular biology and regulatory-aligned documentation to de-risk our partners' programs. She won’t just track timelines; she will manage the entire development lifecycle to eliminate the misalignment and governance gaps that too often stall global programs. By ensuring 100% conviction in our delivery and zero technical gaps in our reporting, she provides the operational backbone that turns our corporate strategy into IND/CMC success.